Working… Menu

A Phase II Study of Locally Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01867892
Recruitment Status : Unknown
Verified May 2013 by National Health Research Institutes, Taiwan.
Recruitment status was:  Enrolling by invitation
First Posted : June 4, 2013
Last Update Posted : June 4, 2013
National Taiwan University Hospital
National Cheng-Kung University Hospital
Information provided by (Responsible Party):
National Health Research Institutes, Taiwan

Brief Summary:

The primary end point is to evaluate the 9-month progression free survival rate and safety profile after FOLFIRINOX versus GOFL induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer.

The secondary end points are to evaluate the disease control rate, overall survival time, toxicity profile and compliance after induction chemotherapy and concurrent chemoradiotherapy as well as the disease control rate after inductional chemotherapy alone in locally advanced pancreatic cancer. Translational research including pharmacogenomic study and biomarker study will also be done concomitantly.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT Drug: ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT Phase 2

Detailed Description:

Patients should be randomized to two study arms stratified by resectability status (borderline resectable and unresectable) after enrollment. Eligible patients will be randomly assigned on a 1:1 basis to either of two study groups, using a central randomization procedure with stratification according to NCCN criteria of resectability.

After randomization, induction chemotherapy (ICT) will be administered for 3 cycles (3 months). Patients who have radiological evidence of distant dissemination will be shifted to salvage chemotherapy. Patients who have responsive, stable disease as well as those with localized progressive disease after ICT will receive concurrent chemoradiotherapy (CCRT) 3-4 weeks after the last dose of ICT. Surgical evaluation will be performed 4-6 weeks after the completion of CCRT. Patients who have respectable disease will undergo surgical resection. Postoperative adjuvant chemotherapy for 3 cycles (3 months) will be given for those who are considered to have curative resection. Patients who still have unresectable disease or non-curative resection will receive systemic chemotherapy till disease progression or unacceptable toxicity.

For Arm 1, ICT with FOLFIRINOX ( oxaliplatin 85mg/m2 for 2 hr, irinotecan 180mg/m2 for 90 min and 5FU 3000mg/m2 + LV 150mg/m2 continuous infusion 48 hr) will be administered biweekly. For Arm 2, ICT with GOFL ( 800mg/m2 gemcitabine at a fixed rate of 10mg/m2/min followed by a 2-hour oxaliplatin 85mg/m2 and then a 48-hour 3000mg/m2 5-FU and 150 mg/m2 leucovorin on day 1 and 15 every 28 days/cycle) will be given biweekly.

After three 3 cycles of ICT, patients without distant metastasis will be given CCRT with 5-FU 450mg/m2 in Arm 1, gemcitabine 400mg/m2 in Arm 2, 2 hrs before RT on day1,8,15,22,29,36. Radiation will be given 180cGy per day, 5 days a week for 28 fractions to totally 5040cGy.

If complete surgical resection is feasible, optimal surgery will be performed 4-6 weeks after CCRT. If complete surgical resection is impossible, biopsy with or without bypass surgery may be performed. Patients who have curative surgical resection will receive additional 6 cycles ( 6 months) of adjuvant chemotherapy ( Arm1, FOLFIRINOX, Arm 2, GOFL) within 4 weeks after surgery and then followed up until tumor progression. Patients who are not feasible for curative resection, will receive continued chemotherapy (Arm1, FOLFIRINOX; Arm2, GOFL) 3-4 weeks after CCRT complete. The regimen will continue till disease progression.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer
Study Start Date : June 2013
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2019

Arm Intervention/treatment
Experimental: ICT of oxaliplatin,irinotecan,5-FU and leucovorinon and CCRT
Arm1:oxaliplatin,irinotecan,5-FU and leucovorinon D1,15 every 28days for 3 cycles,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
Drug: ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT
oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
Other Name: ICT of oxapliplatin,irinotecan,leucovorin,and fluorouracil and CCRT

Active Comparator: ICT of gemcitabine,oxaliplatin,5-FU,leucovorin and CCRT
Arm 2:gemcitabine,oxaliplatin,5-FU,leucovorin on D1,15 every 28 days for 3 cycles,Evaluation of Tumor Response,CR/PR/SD or localized disease RT 5,040cGy in 28 fractions/ 5.5 wks Arm 2: Gem 400mg/m2 iv 40min weekly
Drug: ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT
Gem ,Oxa ,5FU +LV ,RT 5,040cGy in 28 fractions/5.5 wks and Gem 400mg/m2 iv 40min weekly
Other Name: ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil +CCRT

Primary Outcome Measures :
  1. the response rate, disease control rate, overall survival, and patients' quality of life. [ Time Frame: 4.5 years ]
    This is a randomized phase II trial of ICT followed by CCRT with radiotherapy in LAPC. The efficacy will be primarily measured by progression free survival (PFS) as defined in Section 8.5.Other measurements include the response rate, disease control rate, overall survival, and patients' quality of life as described in Section 8.We anticipate that the attrition rate is about 10%, hence, roughly 86 patients will be recruited , we anticipate that the recruitment will be completed in 4.5 years.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have histologically or cytologically confirmed adenocarcinoma of the exocrine pancreas.
  2. Patients must have locally advanced pancreatic cancer (LAPC).
  3. Patients must have LAPC evaluated by radiologist and/or surgeon according to either abdominal CT or MRI, or intra-operative findings.

    • Locally advanced unresectable disease was defined by CT or MRI images as low-density tumor (primary and/or lymphadenopathy) with

      1. extension to the celiac axis or superior mesenteric artery,
      2. occlusion of the superior mesenteric-portal venous confluence
      3. aortic, inferior vena cava (IVC) invasion or encasement
      4. invasion of SMV below transverse mesocolon or unresectable after surgical exploration.

    Those who had superior mesenteric vein impingement, superior mesenteric artery abutment were defined as borderline resectable.

    Those who had superior mesenteric vein occlusion, superior mesenteric artery encasement were defined as unresectable.

  4. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan. See section 8.2 for the evaluation of measurable disease.
  5. Age >20 years and ≦70 years.
  6. ECOG performance score of 0 or 1; see Appendix A.
  7. Patients must have normal organ and marrow function as defined below:

    • absolute neutrophil count >1,500/mL
    • platelets >100,000/mL
    • total bilirubin <1.5X institutional upper limit of normal
    • ALT(SGPT) <5 X institutional upper limit of normal
    • creatinine within normal institutional limits or creatinine clearance>60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
  8. Patients who present with jaundice will be allowed to enroll after control with temporary or permanent internal/external drainage.
  9. The effects of study agents on the developing human fetus at the recommended therapeutic dose are unknown. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
  10. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  1. Patients with distant metastases are not eligible.
  2. Patients with endocrine or acinar pancreatic carcinoma.
  3. Patients may be receiving any steroid, immunologic or other investigational agents within 4 weeks prior to enrollment.
  4. Patients who have had prior chemotherapy or radiotherapy are not eligible.
  5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents used in the study.
  6. Patients who have above grade II peripheral neuropathy.
  7. Patients who had non-curable second primary malignancy within five years, except for non-melanoma skin cancer.
  8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  9. Pregnant women are excluded from this study because the study agents has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with study agents, breastfeeding should be discontinued if the mother is treated with the study agents.
  10. Those who are immuno-compromised or receiving immuno-suppressive therapy are excluded from the study because of increased risk of lethal infections and possible pharmacokinetic interactions with study agent administered during the study.
  11. Those who have chronic diarrhea.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01867892

Sponsors and Collaborators
National Health Research Institutes, Taiwan
National Taiwan University Hospital
National Cheng-Kung University Hospital
Layout table for investigator information
Principal Investigator: Yen-Shen Shen, M.D. National Cheng-Kung University Hospital
Principal Investigator: Chih-Hung Hsu, Ph.D. National Taiwan University Hospital
Principal Investigator: Ruey-Kuen Hsieh, M.D. Mackay Memorial Hospital
Principal Investigator: Jen-Shi Chen, M.D. Chang Gung Memorial Hospital

Layout table for additonal information
Responsible Party: National Health Research Institutes, Taiwan Identifier: NCT01867892     History of Changes
Other Study ID Numbers: T2212
First Posted: June 4, 2013    Key Record Dates
Last Update Posted: June 4, 2013
Last Verified: May 2013
Keywords provided by National Health Research Institutes, Taiwan:
Locally Advanced Pancreatic Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Pancreatic Diseases
Digestive System Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors